Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease A Randomized Controlled Trial
Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease A Randomized Controlled Trial
复制标题
DOI：
10.1016/j.jacc.2009.03.066
复制
发表时间：
2009-08-04
影响因子：
24
通讯作者：
Townend, Jonathan N.
中科院分区：
文献类型：
--
作者：
Edwards, Nicola C.;Steeds, Richard P.;Townend, Jonathan N.
目的探讨血管紧张素转换酶(ACE)抑制剂和血管紧张素受体阻滞剂(ARB)联合应用螺内酯是否能改善早期慢性肾脏病(CKD)患者的左心室重量和动脉僵硬程度。背景慢性肾脏疾病与心血管疾病的高风险、左室肥厚和动脉僵硬的高发生率相关，从而导致不良预后。这些异常被认为部分是肾素-血管紧张素-醛固酮系统激活的结果。方法经螺内酯25 mg每日一次的活跃磨合期后，112例CKD患者的血压控制良好(日间平均动态血压
Objectives We sought to determine whether the addition of spironolactone to angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) improves left ventricular mass and arterial stiffness in early-stage chronic kidney disease (CKD).Background Chronic kidney disease is associated with a high risk of cardiovascular disease and a high prevalence of left ventricular hypertrophy and arterial stiffness that confer an adverse prognosis. It is believed that these abnormalities are in part a result of activation of the renin-angiotensin-aldosterone system.Methods After an active run-in phase with spironolactone 25 mg once daily, 112 patients with stage 2 and 3 CKD with good blood pressure control (mean daytime ambulatory blood pressure